Active, not recruitingPhase 3NCT03246529
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
Studying Multiple myeloma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioLineRx, Ltd.
- Principal Investigator
- John DiPersio, MD, PA-CWashington University School of Medicine
- Intervention
- BL-8040 1.25 mg/kg + G-CSF(drug)
- Enrollment
- 180 target
- Eligibility
- 18-78 years · All sexes
- Timeline
- 2018 – 2029
Study locations (18)
- UCLA Medical Center, Los Angeles, California, United States
- University of Florida, Gainesville, Florida, United States
- University of Miami, Miami, Florida, United States
- Loyola University Medical Center, Chicago, Illinois, United States
- University of Maryland, Baltimore, Maryland, United States
- Mayo Clinic, Rochester, Minnesota, United States
- The Washington University School of Medicine, St Louis, Missouri, United States
- University of Cincinnati, Cincinnati, Ohio, United States
- MD Anderson Cancer Center, Houston Texas, Texas, United States
- Huntsman Cancer Institute in University of Utah, Salt Lake City, Utah, United States
- University of Koln, Cologne, Koln, Germany
- Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, Hungary
- University of Debrecen, Debrecen, Hungary
- Div. Clinicizzata di Ematologia - Policlinico Vittorio Emanuele, Catania, Italy
- Presidio Ospedaliero Morelli Viale Europa, Reggio Calabria, Italy
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03246529 on ClinicalTrials.govOther trials for Multiple myeloma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07225738A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsCity of Hope Medical Center
- RECRUITINGPHASE3NCT06980480A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple MyelomaTakeda
- RECRUITINGPHASE4NCT07094048Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell EngagerCHU de Quebec-Universite Laval
- RECRUITINGPHASE3NCT07222761A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Regeneron Pharmaceuticals
- RECRUITINGNANCT07226934An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic CancersWashington University School of Medicine
- RECRUITINGEARLY PHASE1NCT07294625A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1NCT07179679A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06514508Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma PatientsGuangzhou Gloria Biosciences Co., Ltd.